These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34108971)

  • 21. The role of monocytes in ANCA-associated vasculitides.
    Brunini F; Page TH; Gallieni M; Pusey CD
    Autoimmun Rev; 2016 Nov; 15(11):1046-1053. PubMed ID: 27491570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner.
    Long Y; Chen R; Yu X; Tong Y; Peng X; Li F; Hu C; Sun J; Gong L
    Cancer Immunol Res; 2023 Feb; 11(2):241-260. PubMed ID: 36484740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of CMTM6 protein in hepatocellular carcinoma involving the regulation of the immune microenvironment.
    Wei Z; Guo X; Li D; Wang J; Lin C; Tan C; Wang Y; Zhu X; Tan S
    Int J Biol Macromol; 2024 Aug; 275(Pt 2):133618. PubMed ID: 38971275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Streptococcal Pyrogenic Exotoxin A-Stimulated Monocytes Mediate Regulatory T-Cell Accumulation through PD-L1 and Kynurenine.
    Giesbrecht K; Förmer S; Sähr A; Heeg K; Hildebrand D
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody.
    Jia XM; Long YR; Yu XL; Chen RQ; Gong LK; Geng Y
    Acta Pharmacol Sin; 2023 May; 44(5):1095-1104. PubMed ID: 36418428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CMTM6: increased circulating level and up-regulated expression in labial salivary glands in patients with primary Sjogren's syndrome.
    Qian S; Xu J; Zhao S; Yang P; Yang C
    Clin Exp Immunol; 2022 Jan; 207(1):65-71. PubMed ID: 35020842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease.
    Weyand CM; Berry GJ; Goronzy JJ
    J Leukoc Biol; 2018 Mar; 103(3):565-575. PubMed ID: 28848042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.
    Mezzadra R; Sun C; Jae LT; Gomez-Eerland R; de Vries E; Wu W; Logtenberg MEW; Slagter M; Rozeman EA; Hofland I; Broeks A; Horlings HM; Wessels LFA; Blank CU; Xiao Y; Heck AJR; Borst J; Brummelkamp TR; Schumacher TNM
    Nature; 2017 Sep; 549(7670):106-110. PubMed ID: 28813410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
    Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of BCLAF-1 in PD-L1 stabilization in response to ionizing irradiation.
    Ma Z; Wang H; Meng F; Han Y; Chen Y; Xiao M; Jiang H; Yu Z; Xu B
    Cancer Sci; 2021 Oct; 112(10):4064-4074. PubMed ID: 34251713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis.
    Zhang H; Watanabe R; Berry GJ; Vaglio A; Liao YJ; Warrington KJ; Goronzy JJ; Weyand CM
    Proc Natl Acad Sci U S A; 2017 Feb; 114(6):E970-E979. PubMed ID: 28115719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
    Zhang S; Yan Q; Wei S; Feng X; Xue M; Liu L; Cui J; Zhang Y
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Aug; 132(2):202-209. PubMed ID: 34034998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon-gamma increases monocyte PD-L1 but does not diminish T-cell activation.
    Galbraith NJ; Walker SP; Gardner SA; Bishop C; Galandiuk S; Polk HC
    Cell Immunol; 2020 Nov; 357():104197. PubMed ID: 32891037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation.
    Xu X; Xie T; Zhou M; Sun Y; Wang F; Tian Y; Chen Z; Xie Y; Wu R; Cen X; Zhou J; Hou T; Zhang L; Huang C; Zhao Q; Wang D; Xia H
    Nat Commun; 2024 May; 15(1):4237. PubMed ID: 38762492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical and prognostic significance of CMTM6/PD-L1 in oncology.
    Yaseen MM; Abuharfeil NM; Darmani H
    Clin Transl Oncol; 2022 Aug; 24(8):1478-1491. PubMed ID: 35278198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoints in autoimmune vasculitis.
    Sato Y; Tada M; Goronzy JJ; Weyand CM
    Best Pract Res Clin Rheumatol; 2024 May; 38(2):101943. PubMed ID: 38599937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer.
    Liu Y; Li X; Zhang H; Zhang M; Wei Y
    Oncogene; 2021 Mar; 40(12):2230-2242. PubMed ID: 33649535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1.
    Bodhankar S; Chen Y; Vandenbark AA; Murphy SJ; Offner H
    J Neuroinflammation; 2013 Sep; 10():111. PubMed ID: 24015822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.
    Kdimati S; Christoph C; Glass Ä; Engel N; Dräger DL; Maletzki C; Becker AS; Zimpfer A
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.